Shareholders Equity (USD $)	Total USD ($)	Number of common shares issued	Capital stock USD ($)	Additional paid-in capital USD ($)	Deficit, accumulated during the development stage USD ($)	Cumulative translation adjustment USD ($)
Beginning Balance, Value at Jul. 13, 2004	$ 1			$ 1
Beginning Balance, Shares Issued at Jul. 13, 2004		294
Net Loss for period	(128,488)				(128,488)
Cumulative translation adjustment	(6,536)					(6,536)
Ending Balance, Value at Oct. 31, 2004	(135,023)			1	(128,488)	(6,536)
Beginning Balance, Shares Issued at Oct. 31, 2004		294
Net Loss for period	(387,667)				(387,667)
Cumulative translation adjustment	(161)					(161)
Shares Issued, Amount		87,999,706
Shares Issued, Value	234,496		88,000	146,496
Ending Balance, Value at Oct. 31, 2005	(288,355)		88,000	146,497	(516,155)	(6,697)
Ending Balance, Shares Issued at Oct. 31, 2005		88,000,000
Net Loss for period	(508,260)				(508,260)
Cumulative translation adjustment	(16,222)					(16,222)
Acquisition of Molecular Pharmacology (USA) Limited - Recapitalization, Shares Issued		43,553,740
Acquisition of Molecular Pharmacology (USA) Limited - Recapitalization, Value	(16,236)		43,554	(59,790)
Cancellation of Common Shares, Amount		(20,000,000)	(20,000)	20,000
Ending Balance, Value at Oct. 31, 2006	(829,073)		111,554	106,707	(1,024,415)	(22,919)
Ending Balance, Shares Issued at Oct. 31, 2006		111,553,740
Net Loss for period	(377,131)				(377,131)
Cumulative translation adjustment	(105,436)					(105,436)
Ending Balance, Value at Jun. 30, 2007	(1,311,640)		111,554	106,707	(1,401,546)	(128,355)
Ending Balance, Shares Issued at Jun. 30, 2007		111,553,740
Net Loss for period	62,296				62,296
Cumulative translation adjustment	(166,483)					(166,483)
Ending Balance, Value at Jun. 30, 2008	(1,415,827)		111,554	106,707	(1,339,250)	(294,838)
Ending Balance, Shares Issued at Jun. 30, 2008		111,553,740
Net Loss for period	(94,366)				(94,336)
Cumulative translation adjustment	219,034					219,034
Ending Balance, Value at Jun. 30, 2009	(1,291,129)		111,554	106,707	(1,433,586)	(75,804)
Ending Balance, Shares Issued at Jun. 30, 2009		111,553,740
Net Loss for period	(117,220)				(117,220)
Cumulative translation adjustment	(78,521)					(78,521)
Ending Balance, Value at Jun. 30, 2010	(1,486,870)		111,554	106,707	(1,550,806)	(154,325)
Ending Balance, Shares Issued at Jun. 30, 2010		111,553,740
Net Loss for period	(121,860)				(121,860)
Cumulative translation adjustment	(357,962)					(357,962)
Ending Balance, Value at Jun. 30, 2011	(1,966,692)		111,554	106,717	(1,672,666)	(512,287)
Ending Balance, Shares Issued at Jun. 30, 2011		111,553,740
Net Loss for period	(179,382)				(179,382)
Cumulative translation adjustment	66,215					66,215
Ending Balance, Value at Jun. 30, 2012	(2,079,859)		111,554	106,707	(1,852,048)	(446,072)
Ending Balance, Shares Issued at Jun. 30, 2012		111,553,740
Net Loss for period	(209,900)				(209,900)
Cumulative translation adjustment	235,886					235,886
Ending Balance, Value at Jun. 30, 2013	(2,053,873)		111,554	106,707	(2,061,948)	(210,186)
Ending Balance, Shares Issued at Jun. 30, 2013		111,553,740
Net Loss for period	(116,928)				(116,928)
Cumulative translation adjustment	(62,053)					(62,053)
Ending Balance, Value at Jun. 30, 2014	$ (2,232,854)		$ 111,554	$ 106,707	$ (2,178,876)	$ (272,239)
Ending Balance, Shares Issued at Jun. 30, 2014		111,553,740